development of tests for weight management, risk of osteoporosis and
-- Gensona(R) Heart Health Results at ACC: In March 2007, Interleukin
Genetics and collaborators at the University of California San Diego
reported at the American College of Cardiology (ACC) annual meeting
that associations between coronary artery disease (CAD) and both
oxidized phospholipids (OxPL) and Lp(a) levels appear to be dependent
on pro-inflammatory variants of the interleukin-1 (IL-1) genes. The
results were statistically significant and showed that patients with
identified genetic variations as measured by Interleukin Genetics'
Gensona(R) Heart Health genetic test had a significantly increased risk
of CAD or acute myocardial infarction.
-- New Program for Obesity Genetic Test: Interleukin Genetics initiated a
program in July 2007 to use its perilipin genetic technology, in-
licensed from Tufts University, to develop a genetic test to guide
medically-supervised weight loss in obese individuals.
-- Expansion of Genetic Testing into Japan and China: Interleukin Genetics
announced in July 2007 the completion of patient enrollment in clinical
studies in Japan and China as part of its preparation for the planned
launch of genetic tests in Asian markets in 2009. The Chinese study
includes 1,300 subjects who have cardiovascular disease or are healthy
controls. The Japanese study enrolled 400 subjects ahead of schedule
and is focused on genetic variations, bone loss and osteoporosis in
post-menopausal women in Japan.
-- Initiation of Osteoarthritis Study: In August 2007, Interleukin
Genetics initiated a study on the genetics of osteoarthritis in
collaboration with New York University Medical Center. The study is
investigating whether over-expression of
|SOURCE Interleukin Genetics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved